Pfizer Asks For Biden’s Co-operation To Incentivize Biosimilar Uptake
As Company’s Biosimilars Turnover Grows By Over 80% In Q1
Pfizer is looking for the Biden administration’s co-operation to address the policy issue of affordability and access to biosimilars. In the first quarter, the company’s biosimilars segment grew by 84% on the back of new launches, especially in the US where biosimilars sales nearly doubled.
